<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669457</url>
  </required_header>
  <id_info>
    <org_study_id>H00021788</org_study_id>
    <nct_id>NCT04669457</nct_id>
  </id_info>
  <brief_title>Pediatric Delirium</brief_title>
  <official_title>Prevention of Emergence Delirium in Pediatric Ambulatory Surgery: Single Blinded Randomized Control Study Comparing Intra-nasal Dexmedetomidine With Oral Midazolam.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preventing emergent delirium in pediatric ambulatory surgery through preoperative use of&#xD;
      intra-nasal Dexmedetomidine and oral Midazolam.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric ambulatory patients will randomly be allocated to one of two groups. Group A which&#xD;
      will receive Dexmedetomidine intra-nasally at a dose of 1 mcg/kg, approximately 15-25 minutes&#xD;
      before entering the operating room or Group B which will receive Midazolam orally at a dose&#xD;
      of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the&#xD;
      operating room. Each subject will receive a Drug Acceptance scale, and Parental Separation&#xD;
      Anxiety Scale (PSAS) mask Acceptance Scale to identify the differences in markers associated&#xD;
      with pediatric delirium. End tidal Sevoflurane value during the surgery and at the time when&#xD;
      patient leaves the OR, amount and dose of oral/rectal acetaminophen given in PACU, child's&#xD;
      behavior for 48 hours post-operatively, and documented intake of oral analgesics will be&#xD;
      collected to identify the reduced need for post-operative analgesia and behaviors associated&#xD;
      with extended pediatric delirium.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized control trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
    <masking_description>The surgeon and post-operative nurses will be masked to the group allocation. Masking will only be revealed if medically necessary.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to onset of pediatric delirium</measure>
    <time_frame>Zero minutes to 48 hours</time_frame>
    <description>Time from when the patient is woken from anesthesia to the onset of delirium.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to offset of pediatric delirium</measure>
    <time_frame>Zero minutes to 48 hours</time_frame>
    <description>Time from onset of delirium to the offset of delirium.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of pediatric delirium</measure>
    <time_frame>Zero minutes to 48 hours</time_frame>
    <description>Total time patient experiences delirium</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Acceptance</measure>
    <time_frame>10-25 minutes prior to surgery</time_frame>
    <description>The willingness of the subject to take the drug was assessed in the pre-operative area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parental Separation Anxiety Scale (PSAS)</measure>
    <time_frame>0-48 hours</time_frame>
    <description>Anxiety score was determined when the child was separated from the parents according to four levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mask Acceptance Scale</measure>
    <time_frame>1-10 minutes prior to surgery</time_frame>
    <description>The child's acceptance of the mask by the anesthesiologist was rated as follows.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End tidal Sevoflurane value</measure>
    <time_frame>0-12 hours</time_frame>
    <description>During the surgery and at the time when patient leaves the OR End tidal Sevoflurane value will be documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue analgesia in PACU</measure>
    <time_frame>0-6 hours post surgery</time_frame>
    <description>The amount and dose of oral/rectal acetaminophen given in PACU was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Home Behavior Analysis</measure>
    <time_frame>12-48 hours</time_frame>
    <description>The child's parents were given a diary to document their behavior for 48 hours post-operatively at home.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral analgesic use</measure>
    <time_frame>Two days post-operative</time_frame>
    <description>Document intake of oral analgesics like acetaminophen or ibuprofen</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pediatric Delirium</condition>
  <arm_group>
    <arm_group_label>Intra-nasal Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra-nasal Dexmedetomidine</intervention_name>
    <description>Subjects will receive Dexmedetomidine intra-nasally in the preoperative area. It will be administered at a dose of 1 mcg/kg, approximately 15-25 minutes before entering the operating room.</description>
    <arm_group_label>Intra-nasal Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Midazolam</intervention_name>
    <description>Subjects will receive Midazolam orally in the preoperative area. It will be administered at a dose of 0.5 mg/kg (with a maximum dose of 20 mg), approximately 10-15 minutes before entering the operating room.</description>
    <arm_group_label>Oral Midazolam</arm_group_label>
    <other_name>Midazolam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects age 3 months to 9 years&#xD;
&#xD;
          -  Scheduled to undergo a myringotomy&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) classification of I - II.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with unrepaired cardiac defects, including cyanotic congenital heart disease.&#xD;
&#xD;
          -  Anyone age 10 years or older.&#xD;
&#xD;
          -  Anyone with an ASA classification of III or higher.&#xD;
&#xD;
          -  Non-English language speaker for whom short form consent is not available.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arlene Williams, RN</last_name>
    <phone>7742897998</phone>
    <email>Arlene.Williams@umassmed.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ryan M DeWolf, BS</last_name>
    <phone>9783021857</phone>
    <email>Ryan.dewolf@umassmemorial.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Richmond, MD</last_name>
      <phone>508-963-9922</phone>
      <email>R.Ian.Richmond@umassmemorial.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>May 7, 2021</last_update_submitted>
  <last_update_submitted_qc>May 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>R. Ian Richmond</investigator_full_name>
    <investigator_title>Assistant Professor, Director of Clinical Operations, Dept of Anesthesiology and Perioperative Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be shared via publication as group data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

